Market Research Logo

Huntingtin (Huntington Disease Protein or HTT) - Pipeline Review, H2 2018

Huntingtin (Huntington Disease Protein or HTT) - Pipeline Review, H2 2018

Summary

According to the recently published report 'Huntingtin - Pipeline Review, H2 2018'; Huntingtin (Huntington Disease Protein or HTT) pipeline Targe


Introduction
Global Markets Direct Report Coverage
Huntingtin (Huntington Disease Protein or HTT) - Overview
Huntingtin (Huntington Disease Protein or HTT) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Products under Development by Universities/Institutes
Huntingtin (Huntington Disease Protein or HTT) - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Huntingtin (Huntington Disease Protein or HTT) - Companies Involved in Therapeutics Development
AFFiRiS AG
Exicure Inc
F. Hoffmann-La Roche Ltd
Neurimmune Holding AG
nLife Therapeutics SL
PTC Therapeutics Inc
reMYND NV
Shire Plc
UniQure NV
Voyager Therapeutics Inc
Vybion Inc
WAVE Life Sciences Ltd
Huntingtin (Huntington Disease Protein or HTT) - Drug Profiles
AMT-130 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Antisense Oligonucleotide to Inhibit Huntingtin Protein for Huntington's Disease - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Antisense Oligonucleotides to Inhibit HTT for Huntington's Disease - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Gene Therapy to Inhibit Huntingtin Protein for Huntington’s Disease - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
INT-41 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
NI-302 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
NLF-HD XXXX - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Oligonucleotide to Inhibit HTT for Huntington Disease - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
P-301905 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
RG-6042 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit Huntingtin Protein for Huntington’s Disease - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Synthetic Peptide to Inhibit Huntingtin Protein for Huntington's Disease - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Vaccine to Target Huntingtin for Huntington's Disease - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
VYHTT-01 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
WVE-120101 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
WVE-120102 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Huntingtin (Huntington Disease Protein or HTT) - Dormant Products
Huntingtin (Huntington Disease Protein or HTT) - Product Development Milestones
Featured News & Press Releases
Aug 03, 2018: PRIME designation granted by European Medicines Agency for RG6042 for treatment of Huntington’s disease
May 17, 2018: Voyager Therapeutics Announces New Data on VY-HTT01 at the American Society of Gene and Cell Therapy 2018 Annual Meeting
Apr 25, 2018: uniQure Delivers Oral Presentation on Broad Set of Preclinical Data on AMT-130 in Huntington’s Disease at the 2018 American Academy of Neurology Annual Meeting
Apr 24, 2018: New Data from IONIS-HTT Rx Phase 1/2 Study Demonstrates Correlation Between Reduction of Disease-causing Protein and Improvement in Clinical Measures of Huntington's Disease
Apr 15, 2018: Genentech to Present Phase I/IIa Data of RG6042 at AAN
Apr 03, 2018: Patent Issues for Novel Huntington and Alzheimer's Disease Gene Therapy
Mar 01, 2018: IONIS-HTT Rx (RG6042) Top-Line Data Demonstrate Significant Reductions of Disease-Causing Mutant Huntingtin Protein in People with Huntington's Disease
Jan 22, 2018: uniQure Receives Orphan Medicinal Product Designation in Europe for AMT-130 in Huntington's disease
Dec 13, 2017: New drug could halt progression of Huntington’s disease
Oct 18, 2017: uniQure Presents New Preclinical Data on AMT-130 in Huntington’s Disease at the ESGCT 25th Anniversary Congress in Berlin
Oct 06, 2017: UniQure Announces FDA Orphan Drug Designation for AMT-130 in Huntington’s disease
Jul 17, 2017: Wave Life Sciences Initiates Phase 1b/2a Clinical Trial: PRECISION-HD1 in Patients with Huntington's Disease
Jul 17, 2017: Wave Life Sciences Announces Initiation of Phase 1b/2a Clinical Trial: PRECISION-HD2 in Patients with Huntington's Disease
Jun 22, 2017: Enrollment in Phase 1/2a Study of IONIS-HTT Rx in Patients with Huntingtons Disease Completed and Open-Label Extension Study to Open in 2H 2017
Jun 01, 2017: Voyager Therapeutics Selects Lead Clinical Candidate for Huntington's Disease
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
List of Tables
Number of Products under Development by Stage of Development, H2 2018
Number of Products under Development by Therapy Areas, H2 2018
Number of Products under Development by Indication, H2 2018
Number of Products under Development by Companies, H2 2018
Products under Development by Companies, H2 2018
Number of Products under Investigation by Universities/Institutes, H2 2018
Products under Investigation by Universities/Institutes, H2 2018
Number of Products by Stage and Mechanism of Actions, H2 2018
Number of Products by Stage and Route of Administration, H2 2018
Number of Products by Stage and Molecule Type, H2 2018
Pipeline by AFFiRiS AG, H2 2018
Pipeline by Exicure Inc, H2 2018
Pipeline by F. Hoffmann-La Roche Ltd, H2 2018
Pipeline by Neurimmune Holding AG, H2 2018
Pipeline by nLife Therapeutics SL, H2 2018
Pipeline by PTC Therapeutics Inc, H2 2018
Pipeline by reMYND NV, H2 2018
Pipeline by Shire Plc, H2 2018
Pipeline by UniQure NV, H2 2018
Pipeline by Voyager Therapeutics Inc, H2 2018
Pipeline by Vybion Inc, H2 2018
Pipeline by WAVE Life Sciences Ltd, H2 2018
Dormant Projects, H2 2018
List of Figures
Number of Products under Development by Stage of Development, H2 2018
Number of Products under Development by Therapy Areas, H2 2018
Number of Products under Development by Top 10 Indications, H2 2018
Number of Products by Mechanism of Actions, H2 2018
Number of Products by Stage and Mechanism of Actions, H2 2018
Number of Products by Routes of Administration, H2 2018
Number of Products by Stage and Top 10 Routes of Administration, H2 2018
Number of Products by Molecule Types, H2 2018
Number of Products by Stage and Molecule Types, H2 2018

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report